United States Chronic Obstructive Pulmonary Disease Drug Markets

 


Availability: In stock

 

Regular Price: USD 3,950

Special Price USD 2,765

* Required Fields

Regular Price: USD 3,950

Special Price USD 2,765

PAY BY INVOICE

Be the first to review this product

Table of Contents

United States Chronic Obstructive Pulmonary Disease Drug Markets, Executive SummaryIntroduction to the COPD Drug Therapy MarketObjectives and PurposeReport Scope and SegmentationReport StructurePatient Population StatisticsSummary of Major FindingsTotal Revenues and Revenue Growth RatesAnalysis by Major SegmentCompetitive AnalysisUnited States Chronic Obstructive Pulmonary Disease Drug Markets, Market Engineering Research MethodologyFrost & Sullivan's Market Engineering Forecasting Methodology for the Pharmaceutical IndustryFrost & Sullivan's Market Engineering Forecasting Methodology for the Pharmaceutical IndustryResearch SourcesSecondary SourcesPrimary ResearchIndustry Specific Forecast ModelIndustry Specific Forecast ModelPopulation-Based ForecastProduct-Based ForecastMarket Model AssumptionsPresentation of Market Engineering Measurements, Definition and their Strategic SignificancePresentation of Market Engineering Measurements, Definition and their Strategic SignificanceGlossary of TermsList of AcronymsList of DefinitionsUnited States Chronic Obstructive Pulmonary Disease Drug Markets, Challenges in the COPD Drug Therapy MarketIntroductionIntroductionDiversity of Providers Limits Targeted Marketing CampaignsPoor Diagnostic Capability Retards Revenue GrowthLack of Understanding of Disease Pathology Deters Development of Curative TreatmentsDeveloping Curative Treatment Initiates Market ExpansionLow Product Penetration Rates Plummet Market GrowthUsage of Generic Names When Prescribing Erodes Brand Name Recognition"Trial-and-Error" Treatment Protocols Lower Product AcceptanceTreating a Geriatric Patient Population Challenges Market ParticipantsConversion of Delivery Technology from Asthma to COPD Propels R&DKeeping Ahead of Competition Determines Market LeadersMarket Engineering Research for the Existing U.S. COPD Drug Therapies Market 1994-2004Total Market AnalysisMarket Overview and DefinitionsDisease OverviewDisease Population Estimates and TrendsCurrent Treatment PathwaysDrug Delivery SystemsMarket Engineering Research Measurement SystemMarket Engineering Revenue Forecasts (1994-2004)Market Engineering Estimates for Bronchodilator COPD Drug Therapy MarketMarket Overview and DefinitionsMarket Engineering Research Measurement SystemMarket DriversMarket RestraintsMarket Engineering Revenue Forecasts (1994-2004)Competitive AnalysisProduct AnalysisMarket Engineering Estimates for Inhaled Corticosteroid COPD Therapy MarketMarket Overview and DefinitionsMarket Engineering Research Measurement SystemMarket DriversMarket RestraintsMarket Engineering Revenue Forecasts (1994-2004)Competitive AnalysisProduct AnalysisUnited States Chronic Obstructive Pulmonary Disease Drug Markets, U.S. Emerging COPD Therapy Market 1998-2004IntroductionIntroductionResearch Focus in Symptom ManagementResearch Focus in Symptom ManagementBronchodilatorsAnti-Inflammatory/Corticosteroid DrugsMucus ExpectorantsResearch Focus in Reversing Lung DamageOverviewGene TherapyImmunotherapyProteinase InhibitorsProducts In the PipelineProducts In the PipelineHP-3 (Milkhaus Laboratory)Ariflo (SmithKline Beecham)AAT Deficiency Emphysema Gene Replacement Therapy (Gene Medicine)ZD0892 (Zeneca)GW311616 (Glaxo Wellcome)SB223412 (SmithKline Beecham)United States Chronic Obstructive Pulmonary Disease Drug Markets, Market Engineering StrategyMarket Engineering Strategic RecommendationsMarket Engineering Strategic RecommendationsMarketing DepartmentResearch and Development DepartmentSales DepartmentBusiness Development DepartmentCorporate Management




Related Research

Release Date : 26-Jul-17

Region : North America

Release Date : 25-Jul-17

Region : North America

Release Date : 24-Jul-17

Region : North America

Release Date : 24-Jul-17

Region : North America

Release Date : 21-Jul-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.